Loading
institutionsInstitution
University of Colorado Cancer Center
The University of Colorado Cancer Center serves the Rocky Mountain states; its thoracic oncology group defined how ALK, ROS1 and NTRK fusion-driven lung cancers behave and helped bring crizotinib, entrectinib and larotrectinib to patients, and it holds a lung cancer SPORE grant.
Also called: CU Cancer Center
Overview
NCI-designated since 1988 and comprehensive since 1997, the CU Cancer Center on the Anschutz Medical Campus serves Colorado and the surrounding mountain states. Its thoracic oncology group, built by Paul Bunn and Fred Hirsch and continued by Ross Camidge and Robert Doebele, defined the clinical behaviour of ALK, ROS1 and NTRK fusion-driven lung cancers and helped bring crizotinib, entrectinib and larotrectinib to patients. The centre holds a lung cancer SPORE, and its partners include UCHealth and Children's Hospital Colorado.
Location
Aurora, CO, US
Type
cancer center · University of Colorado Anschutz Medical Campus
Newsweek 2026 oncology rank
Not in top 300 listing used
NCI designation
comprehensive
OnCo score
#92 · 41 points (0 Newsweek + 15 NCI + 26 from 13 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-01.
Matched to University of Colorado Cancer Center, including child institutions. 478 works · 12,554 citations · 68% open access · 23% clinical trials · 1% reviews.
Oncology works per year
932022
1092023
1062024
1012025
692026
Most works
- Manali Kamdar38 works
- Christopher Hanyoung Lieu35 works
- Wells A. Messersmith33 works
- Virginia F. Borges30 works
- Jeremy S. Abramson25 works
- Junxiao Hu21 works
- Theresa Michelle Medina21 works
- Matthew Alexander Lunning21 works
- Marco Del Chiaro20 works
- Alexis Diane Leal17 works
Most cited
- Oncogene-driven lung cancer
- Lung cancer SPORE
- Paediatric oncology (Children's Colorado)
Bryan R. Haugen
Professor of Medicine and Head of Endocrinology, University of Colorado
Differentiated thyroid cancerThyroid nodulesClinical guidelines
Colorado endocrinologist who chaired the 2015 American Thyroid Association guidelines, the reference for how thyroid nodules and differentiated thyroid cancer are diagnosed and treated.
D. Ross Camidge
Joyce Zeff Chair in Lung Cancer Research, University of Colorado Cancer Center
ALK-positive lung cancerOncogene-driven NSCLCBrain metastases
Led the crizotinib and brigatinib trials that defined ALK-targeted lung cancer therapy.
Richard Schulick
Director
Surgical oncologyPancreatic cancerHepatobiliary surgery
Pancreatic cancer surgeon who has directed the University of Colorado Cancer Center, the state's NCI-designated comprehensive cancer centre, since 2018.
Sapna P. Patel
Professor of Medicine and Director of Melanoma Medical Oncology, University of Colorado Cancer Center
MelanomaNeoadjuvant immunotherapyUveal melanoma
Led SWOG S1801, the trial that showed giving pembrolizumab before surgery, not just after, improves outcomes in melanoma.
Similar pages
- TrialPROFILE 1001 ROS1 expansion cohort
Shares ROS1, Entrectinib, Oncogene addiction, Crizotinib.
- Key paperFirst-line lorlatinib or crizotinib in advanced ALK-positive lung cancer
Shares D. Ross Camidge, ROS1, Oncogene addiction, Lorlatinib.
- Key paperALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer
Shares ROS1, Lorlatinib, Crizotinib, Gene fusion.
- CancerInflammatory myofibroblastic tumour (IMT)
Shares ROS1, Larotrectinib, Entrectinib, NTRK.
- Key paperROS1 rearrangements define a unique molecular class of lung cancers
Shares ROS1, Crizotinib, Gene fusion, ALK.
- TrialA Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
Shares Entrectinib, Crizotinib, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
- PairingSequence: targeted therapy before immunotherapy in driver-positive NSCLC
Shares ROS1, Lorlatinib, ALK, Small-molecule kinase inhibitors.
- BiomarkerROS1 fusion (ROS1-positive)
Shares ROS1, Entrectinib, Crizotinib, Gene fusion.
cancers
fronts
technologies
targets
drugs
ApprovedSmall-molecule ALK/ROS1/MET TKI (first generation)
Crizotinib · Xalkori
ApprovedSmall-molecule TRK/ROS1/ALK TKI (CNS-penetrant)
Entrectinib · Rozlytrek
ApprovedSmall-molecule pan-TRK inhibitor (first generation)
Larotrectinib · Vitrakvi
ApprovedSmall-molecule kinase inhibitor (ALK/ROS1)
Lorlatinib · Lorbrena